Diabetes mellitus, where treatment with insulin is required. When should this drug be used

When should this drug be used (Therapeutic indications)

Diabetes mellitus, where treatment with insulin is required.

Composition
Each ml of the solution for injection contains 100 IU insulin glargine (Insulin glargine). Insulin glargine is a human insulin analogue designed to have a long dissolution profile at neutral pH. At pH 4, insulin glargine is a human insulin analogue designed to have a low solubility at neutral pH.

Presentation
Lantus® is available as 100 IU/ml insulin glargine as a sterile, pyrogen-free, water-based solution for injection.

Expiry date
Vial containing 10 ml (100 IU).

Manufacturers/Marketing Authorisation Holder

Legal Category
L13840/06

Warning and Precautions
This product is a long-acting insulin. Insulin glargine is a human insulin analogue designed to have a long dissolution profile at neutral pH. At pH 4, insulin glargine.

Interactions
An increased or decreased susceptibility to hypoglycaemia may occur in concomitant use of, e.g., oral antidiabetic agents, A1C inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and sodium-glucose cotransporter-2 (SGLT-2) inhibitors.

Storage
Store below 25°C (59°F). Do not freeze. Protect from light. Avoid direct contact of the vial with the refrigeration unit.

Expiration date
Do not use at the date of expiration.

Presentation
Vial containing 10 ml (100 IU).

Manufacturers/Marketing Authorisation Holder

Legal Category
L13840/06

Warning and Precautions
This product is a long-acting insulin. Insulin glargine is a human insulin analogue designed to have a long dissolution profile at neutral pH. At pH 4, insulin glargine.

Interactions
An increased or decreased susceptibility to hypoglycaemia may occur in concomitant use of, e.g., oral antidiabetic agents, A1C inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and sodium-glucose cotransporter-2 (SGLT-2) inhibitors.

Storage
Store below 25°C (59°F). Do not freeze. Protect from light. Avoid direct contact of the vial with the refrigeration unit.

Expiration date
Do not use at the date of expiration.

Presentation
Vial containing 10 ml (100 IU).

Manufacturers/Marketing Authorisation Holder

Legal Category
L13840/06

Warning and Precautions
This product is a long-acting insulin. Insulin glargine is a human insulin analogue designed to have a long dissolution profile at neutral pH. At pH 4, insulin glargine.

Interactions
An increased or decreased susceptibility to hypoglycaemia may occur in concomitant use of, e.g., oral antidiabetic agents, A1C inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and sodium-glucose cotransporter-2 (SGLT-2) inhibitors.

Storage
Store below 25°C (59°F). Do not freeze. Protect from light. Avoid direct contact of the vial with the refrigeration unit.

Expiration date
Do not use at the date of expiration.

Presentation
Vial containing 10 ml (100 IU).

Manufacturers/Marketing Authorisation Holder

Legal Category
L13840/06

Warning and Precautions
This product is a long-acting insulin. Insulin glargine is a human insulin analogue designed to have a long dissolution profile at neutral pH. At pH 4, insulin glargine.

Interactions
An increased or decreased susceptibility to hypoglycaemia may occur in concomitant use of, e.g., oral antidiabetic agents, A1C inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and sodium-glucose cotransporter-2 (SGLT-2) inhibitors.

Storage
Store below 25°C (59°F). Do not freeze. Protect from light. Avoid direct contact of the vial with the refrigeration unit.

Expiration date
Do not use at the date of expiration.

Presentation
Vial containing 10 ml (100 IU).

Manufacturers/Marketing Authorisation Holder

Legal Category
L13840/06

Warning and Precautions
This product is a long-acting insulin. Insulin glargine is a human insulin analogue designed to have a long dissolution profile at neutral pH. At pH 4, insulin glargine.

Interactions
An increased or decreased susceptibility to hypoglycaemia may occur in concomitant use of, e.g., oral antidiabetic agents, A1C inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and sodium-glucose cotransporter-2 (SGLT-2) inhibitors.

Storage
Store below 25°C (59°F). Do not freeze. Protect from light. Avoid direct contact of the vial with the refrigeration unit.

Expiration date
Do not use at the date of expiration.

Presentation
Vial containing 10 ml (100 IU).

Manufacturers/Marketing Authorisation Holder

Legal Category
L13840/06

Warning and Precautions
This product is a long-acting insulin. Insulin glargine is a human insulin analogue designed to have a long dissolution profile at neutral pH. At pH 4, insulin glargine.

Interactions
An increased or decreased susceptibility to hypoglycaemia may occur in concomitant use of, e.g., oral antidiabetic agents, A1C inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, and sodium-glucose cotransporter-2 (SGLT-2) inhibitors.

Storage
Store below 25°C (59°F). Do not freeze. Protect from light. Avoid direct contact of the vial with the refrigeration unit.

Expiration date
Do not use at the date of expiration.
153763
153763/3

Auftrags-Nummer: 075850

Nein

Technische Freigabe: Druckfertig

Gesamtfreigabe: Ja

Zweck: Druckfertig

Zweck: Druckfertig